Expression of E-cadherin and beta-catenin in primary and peritoneal metastatic ovarian carcinoma

Citation
T. Fujioka et al., Expression of E-cadherin and beta-catenin in primary and peritoneal metastatic ovarian carcinoma, ONCOL REP, 8(2), 2001, pp. 249-255
Citations number
37
Categorie Soggetti
Oncology
Journal title
ONCOLOGY REPORTS
ISSN journal
1021335X → ACNP
Volume
8
Issue
2
Year of publication
2001
Pages
249 - 255
Database
ISI
SICI code
1021-335X(200103/04)8:2<249:EOEABI>2.0.ZU;2-F
Abstract
Protein expression levels of E-cadherin and beta -catenin were examined in 39 primary and 10 metastatic ovarian carcinoma to elucidate the role of the se molecules in the extension of ovarian carcinoma by immunohistochemistry. Twenty-two of 39 (56%) ovarian carcinomas were preserved type and 17 of 39 (44%) were reduced type of E-cadherin. In contrast, 36 of 39 (92%) ovarian carcinomas were preserved type and 3 of 39 (8%) were reduced type of beta -catenin. E-cadherin expression in well-differentiated carcinoma was higher than that in moderately/poorly-differentiated carcinoma (p<0.05). Interest ingly, 6 of 10 (60%) peritoneal metastatic lesions resulted in the reduced expression of E-cadherin compared with primary lesions. In contrast, only 2 of 10 (20%) metastatic lesions showed reduced expression of <beta>-catenin compared with primary lesions. Mutation of exon 3 of beta -catenin gene wa s rare (3%, 1/39) in carcinoma. These results suggested that the cell adhes ion molecule E-cadherin might play an important role in the formation of pe ritoneal metastasis. In contrast, beta -catenin is not a good indicator of metastasis in human ovarian carcinoma.